NCCN Guideline Recommendation

Submitted by: Ken Surprenant
Organization: unaffiliated (surviving spouse)
Address: 85 Latta Street, Battle Creek, MI, 49017, USA
Phone: 269.274.8875 (cell/text)
Email: kensbc@aol.com or kesbc6@gmail.com
Date of request: 6 April 2014
NCCN Guideline Panel: Breast Cancer

I respectfully request the NCCN Panel for Breast Cancer review the enclosed data for inclusion in the initial diagnostic evaluation of patients preparing to receive treatment with a fluoropyrimidine (e.g. capecitabine, fluorouracil 5-FU).

Specific Changes: Revise the guidelines to recommend pre-screening of patients using a “functional” test that measures the dihydrouracil/uracil ratio to identify individuals with impaired dihydropyrimidine dehydrogenase (DPD) activity for whom the fluoropyrimidine dosage should be reduced to avoid severe toxic reactions; treatments should also rely upon pharmacokinetic follow-up to indicate more precisely recommended dosage levels.

FDA Clearance: not applicable

Rationale: Patients with impaired DPD activity (due to genetic and non-genetic factors) are unable to metabolize the fluoropyrimidine and therefore are at risk of severe toxic reaction; pre-screening patients will improve patient care, treatment efficacy, and significantly reduce grade 3 and 4 toxic reactions and fatalities (instances of severe toxicity range from 10-40%).

The following articles are submitted to support this proposed change: These studies show that severe reactions are far from rare (estimated 500-1000 fatalities/year in the US) and demonstrate that pre-treatment screening and dose management of fluoropyrimidine can effectively reduce the incidence of severe toxic and fatal reactions. (Note: fluoropyrimidines are used also in the treatment of head/neck, and colorectal cancers).

Caudle, KE; Diasio, RB; et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluorouracil Dosing, Clinical Pharmacology & Therapeutics, (29 August 2013), doi:10.1038/clpt.2013.172. This study reports 10-40% of patients with 5-FU suffer severe and sometimes life threatening toxic reactions and recommends starting dosage at 50%, in order to minimize toxicities, followed by an assessment of the patient’s tolerance before increasing dose levels.

Zhu, Andrew; Puchalski, Thomas; et al. Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms and Their Association with 5-Fluorouracil/Leucovorin Chemotherapy in Colorectal Cancer, Clinical Colorectal Cancer, 2004 (Vol 3, No. 4): 225-234. This paper indicates that toxicity is not a
rare condition: 15-20% suffer grade 3, 3-10% grade 4 toxic reactions to 5-FU treatment; between 500-1000 US patients die annually due to 5-FU toxicity.

Ciccolini, Joseph; Mercier, Cedric; et al. Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil-Related Severe Toxicities: Hype or Hope?, *Clinical Colorectal Cancer*, 2010 (Vol 9, No. 4): 224-228. This study indicates non-genetic factors may lower DPD levels and put patients at risk; it reports that functional techniques (uracil/dihydrouracil plasma tests and uracil breath tests) are available to identify patients who have a limited ability to metabolize 5-FU; and it asserts that pre-screening and dose tailoring systematically improved clinical outcomes of 5-FU patients.

Piper, Margaret; Aronson, Naomi; et al. Pharmacogenetic Testing to Predict Serious Toxicity From 5-Fluorouracil (5-FU) for Patients Administered 5-FU-Based Chemotherapy for Cancer, *Technology Evaluation Center, Assessment Program* Vol 24, No. 13, Aug 2010. This study reports 30% of patients receiving this treatment regimen suffer severe toxic reactions; genetic testing has poor predictive value.